RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …

K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix… - 2019 - ascopubs.org
9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
被引用次数：44 相关文章

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …

K Nakagawa, EB Garon, T Seto… - JOURNAL OF …, 2019 - scholarworks.bwise.kr
ScholarWorks@SUNGKYUNKWAN UNIVERSITY: RELAY: A multinational, double-blind,
randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or …